0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Hypothalamic Injection of Cycloheximide in the 4-Day Cyclic Rat

      , ,

      Neuroendocrinology

      S. Karger AG

      Cycloheximide, Cyclic rat, Sex behavior, Ovulation, Hypothalamus

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The results of several studies imply that estrogen can act upon the central nervous system via a protein synthetic step. Our objective was to determine if the intrahypothalamic (preoptic area, POA) injection of cycloheximide (CHX), an inhibitor of protein synthesis, at 17.00 h on diestrus II of the 4-day cycle altered lordotic behavior and (or) ovulation in the intact rat (sexual receptivity to males normally begins on the evening of proestrus as herein defined; ovulation occurs on estrus of the cycle). CHX-treated females were tested for lordotic behavior at 23.00 h on proestrus, then killed at 17.00 h on the following day. None of the CHX-POA rats were receptive to the males and 90% of these rats did not ovulate. Thus, CHX significantly suppressed sex behavior and ovulation in the cyclic rat.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1979
          1979
          26 March 2008
          : 29
          : 4
          : 247-254
          Affiliations
          Department of Physiology and Cell Biology, University of Kansas, Lawrence, and Departments of Anatomy and Gynecology/Obstetrics, R. L. Smith Research Center, University of Kansas Medical Center, Kansas City, Kans.
          Article
          122929 Neuroendocrinology 1979;29:247–254
          10.1159/000122929
          514453
          © 1979 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Categories
          Original Paper

          Comments

          Comment on this article